NCT02709343View on ClinicalTrials.gov

Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 21, 2017

Primary Completion Date

September 13, 2023

Study Completion Date

October 25, 2023

Conditions
Chronic Lung Allograft Dysfunction (CLAD)
Interventions
DRUG

Bone-marrow derived MSCs

Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells

DRUG

Placebo

Placebo product visually very similar to mesenchymal stromal cells

Trial Locations (5)

2010

St Vincents Hospital, Sydney

3000

The Alfred Hospital, Melbourne

4032

The Prince Charles Hospital, Brisbane

5000

Royal Adelaide Hospital, Adelaide

6150

Fiona Stanley Hospital, Murdoch

Sponsors
All Listed Sponsors
collaborator

Isopogen

UNKNOWN

collaborator

Cell and Tissue Therapies

UNKNOWN

lead

The University of Queensland

OTHER

NCT02709343 - Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction | Biotech Hunter | Biotech Hunter